|Awarded On||August 19, 2020|
|Title||Targeted Proteolysis of Glucocorticoid Receptor (GR) as a Therapeutic Strategy to Enhance Anti-Tumor Immunity|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Yonathan Lissanu Deribe|
|Cancer Sites||Lung and Bronchus|
*Pending contract negotiation
Lung cancer is a devastating disease that remains the top cause of cancer mortality and accounts for a quarter of all cancer related deaths. Despite improvements in molecularly targeted therapies and immunotherapies, the majority of patients with lung cancer still lack effective treatment options. The recent introduction of immunotherapy has led to a paradigm shift in the treatment of lung cancer patients. Unfortunately, only a subset of patients respond to currently approved immunotherapies and many patients develop resistance after initial response. Hence, new immunotherapies and drugs that synergize with immunotherapy are urgently needed to further help patients. This proposal is based on...